Trial reportJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2010
A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.
Trial report in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01850979 (Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops), which is not on this map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 178 citations in OpenAlex.
- The impact of tacrolimus therapy on the outcomes of vernal keratoconjunctivitis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial.BMC ophthalmology · 2024Trial
- Alleviation of Allergic Rhinoconjunctivitis Symptoms in Participants Treated with a 0.005% Tacrolimus Eye-Drop Solution.Clinical ophthalmology (Auckland, N.Z.) · 2024Trial
- A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease.Ophthalmology · 2016Trial
- Enigmatic Role of IL-31 in the Itch and Inflammation of Vernal Keratoconjunctivitis.Juntendo medical journal · 2026Article
- Topical Use of Tacrolimus in Corneal and Ocular Surface Pathologies: A Systematic Review.Journal of clinical medicine · 2025Review
- Association between herpes zoster ophthalmicus and the risk of corneal ulcer.Frontiers in medicine · 2025Article
- Article
- Topical tacrolimus versus dexamethasone in managing shield ulcer of vernal keratoconjunctivitis.Medical hypothesis, discovery & innovation ophthalmology journal · 2024Article
- Long-Term Observation of Prognostic Factors and Clinical Outcome of Vernal Keratoconjunctivitis in Childhood.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Article
- Diagnostic approach and grading scheme for canine allergic conjunctivitis.BMC veterinary research · 2023Article
- Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis.American journal of ophthalmology case reports · 2022Article
- Safety and efficacy of topical tacrolimus 0.03% in the management of vernal keratoconjunctivitis: a non-randomized controlled clinical trial.Medical hypothesis, discovery & innovation ophthalmology journal · 2022Article
- A comparative study between ciclosporine A eye drop (2%) and tacrolimus eye ointment (0.03%) in management of children with refractory vernal keratoconjunctivitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Diagnosis, Management, and Treatment of Vernal Keratoconjunctivitis in Asia: Recommendations From the Management of Vernal Keratoconjunctivitis in Asia Expert Working Group.Frontiers in medicine · 2022Review
- Why do scientific advances take so long to be incorporated into clinical practice? The case of intracameral injection of antibiotics to prevent acute endophthalmitis after cataract surgery.Arquivos brasileiros de oftalmologia · 2022Article
- Incremental Concentrations of Tacrolimus Eye Drops as a Strategy for the Management of Severe Vernal Keratoconjunctivitis.Frontiers in pharmacology · 2022Article
- Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients.BMC ophthalmology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
methodsThis was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of objective signs in palpebral and bulbar conjunctiva, limbus, and corneal involvement was assessed using 4 grades. Seven subjective symptoms were evaluated by visual analog scale (VAS) assessment. The primary efficacy endpoint was change in the total score of objective signs at the end of treatment. The secondary efficacy endpoints included change in the score for each objective sign and change in the VAS for each subjective symptom. Safety was assessed based on the severity and the incidence of adverse events.
resultsMean change from baseline in total score for objective signs was significantly greater in the tacrolimus (-5.6 + or - 5.1) than in the placebo group (-0.1 + or - 4.5; P < 0.001). Tacrolimus significantly improved giant papillae (P = 0.001) and corneal involvement (P = 0.005). Five subjective symptoms (itching, discharge, hyperemia, lacrimation, and foreign body sensation) were significantly better in the tacrolimus than in the placebo group. The most frequent treatment-related adverse event in the tacrolimus group was mild ocular irritation upon topical instillation, which was well-tolerated.
conclusionTacrolimus ophthalmic suspension 0.1% is effective in treating severe allergic conjunctivitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.